GET DAILY SIGNALSTeva (TEVA) Q3 2026 Earnings: Branded Growth Offsets Generics Dip with +5.8% Stock Reaction
Key Takeaways
- Teva reported third-quarter 2026 revenue of $4.4 billion, down about 2% year over year but above the roughly $4.2 billion consensus estimate.
- Non-GAAP earnings per share came in at $0.86, a 10% increase from $0.78 a year earlier and well above the $0.72 analyst consensus.
- Growth was driven by branded medicines, with AUSTEDO up 21% to $751 million, AJOVY up 61% to $269 million, and UZEDY nearly doubling to $85 million.
- Generic drug revenue fell about 16% in the quarter, largely reflecting a lower contribution from generic REVLIMID.
- Teva raised its full-year 2026 outlook for the second consecutive quarter, lifting revenue guidance to $16.7–$17.0 billion.
Earnings Context and Its Significance
Teva Pharmaceutical Industries' third-quarter 2026 report serves as an important checkpoint in the company's "Pivot to Growth" strategy. After years of decline, Teva has posted a streak of consecutive growth quarters, yet the latest results show a more nuanced picture: branded franchises are expanding rapidly while the generics business, once the company's core, continues to shrink. From what I see, investors track this report closely because it tests whether margin expansion and innovative-product momentum can offset fading generic revenue. With the company shifting toward a biopharma model, this quarter's results and raised guidance provide a clearer view on whether that transformation is delivering durable profitability and balance-sheet strength.
The Quarter's Reported Figures
For the third quarter of 2026, Teva reported total revenue of $4.4 billion, a decline of roughly 2% from the prior-year period but comfortably above the consensus estimate of about $4.2 billion. Non-GAAP earnings per share reached $0.86, up 10% from $0.78 in the same quarter a year earlier and well ahead of the $0.72 analysts had expected. GAAP net profit was $233 million, down 46% year over year, while non-GAAP net profit rose 11.3% to approximately $1 billion.
Gross margin expanded to 58.7%, an improvement of 345 basis points, and adjusted EBITDA grew 7%. The innovative portfolio rose 33% year over year, led by AUSTEDO ($751 million, up 21%), AJOVY ($269 million, up 61%), and UZEDY ($85 million, up 96%). Generics revenue fell 16%, primarily due to a lower contribution from generic REVLIMID. Management raised 2026 revenue guidance to $16.7–$17.0 billion and set adjusted EPS guidance at $1.92–$2.11. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Investors responded positively to the report, with TEVA's New York-listed shares rising around 5.8% to approximately $43 in morning trading following the release. The combination of an earnings beat, a revenue beat, and a second consecutive guidance increase reinforced confidence that the company's branded-drug strategy is working. Sentiment was further supported by management's confirmation of momentum across AUSTEDO, AJOVY, and UZEDY, which helped offset investor concerns about the structural decline in generics. The company's continued deleveraging and margin expansion also contributed to a more favorable reaction, though the decline in GAAP net profit and the generics headwind remain areas investors are watching closely.
Forward Outlook and Key Factors to Monitor
Following this earnings event, several factors will shape TEVA's trajectory. First, investors should monitor the branded growth engines, particularly AUSTEDO, AJOVY, and UZEDY, whose raised outlooks now anchor the company's near-term growth story. The pace at which these franchises convert strong demand into revenue will be a central driver of performance.
Second, the generics business remains a key swing factor. While the latest decline was largely tied to generic REVLIMID, sustained weakness in this segment could pressure overall top-line growth. Conversely, Teva's biosimilar pipeline represents a potential offset, with management signaling it may reach its 2027 biosimilar revenue target ahead of schedule.
Finally, investors should track margin progression and balance-sheet improvements, as the company continues to prioritize a 30% non-GAAP operating margin target and further debt reduction. Newer launches such as the schizophrenia treatment Weltruza, while not expected to contribute meaningful revenue until later, will be an important catalyst to watch as 2027 and 2028 approach.
Using AI Tools for Portfolio Insights
In my research process, I frequently rely on Tickeron’s AI Screener to quickly filter peers in the specialty pharmaceutical space and spot emerging technical or fundamental signals. The tool helps me compare valuation metrics, volatility patterns, and performance trends across the sector without spending hours on manual analysis, which keeps my workflow efficient when evaluating names like TEVA.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for TEVA shows an upward move is likely
TEVA's Aroon Indicator triggered a bullish signal on October 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 282 similar instances where the Aroon Indicator showed a similar pattern. In 227 of the 282 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 227 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEVA as a result. In 45 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for TEVA turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 25 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.123) is normal, around the industry mean (8.029). P/E Ratio (65.645) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.152). Dividend Yield (0.008) settles around the average of (0.047) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (178.797).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients
Industry PharmaceuticalsGeneric
Advertisement